Could the class of new weight-loss drugs, including semaglutide, approved as Ozempic to treat type 2 diabetes and Wegovy to treat obesity, also reduce addictions and compulsive behaviors?
As demand for semaglutide for weight loss increased following the FDA's approval of Wegovy in June 2021, personal stories of additional unexpected benefits also began to emerge for the class of drugs known as GLP-1, which mimic a natural hormone called glucagon-like peptide. . -1 which helps the person feel full.
Some patients taking these medications for type 2 diabetes or weight loss have also lost interest in addictive and compulsive behaviors such as drinking alcohol, smoking, shopping, nail biting, and scratching. skin, as reported in articles in the New York Times and The Atlantic. , among others. . For now, the reports are purely anecdotal, so they are subjective and have not yet been clinically verified. But there is also some initial research that supports these
